In vitro activity of ceftibuten at sub-inhibitory concentrations in comparison with other antibiotics against respiratory and urinary tract pathogens

Journal of Chemotherapy

Volumn 19, Issue 2, 2007, Pages 152-160

  Maioli, E ^b   Marchese, A ^b   Roveta, S ^b   Cagnacci, S ^b   Cavallini, F ^b   Cassanelli, C ^b   Gualco, L ^b   Debbia, E A ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b NONE

Author keywords

Ceftibuten; Respiratory pathogens; Urinary pathogens

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; CEFACLOR; CEFPODOXIME; CEFTIBUTEN; CLARITHROMYCIN; COTRIMOXAZOLE; TELITHROMYCIN;

ARTICLE; BACTERIUM ADHERENCE; BIOFILM; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG STABILITY; EPITHELIUM CELL; ESCHERICHIA COLI; HYDROPHOBICITY; IN VITRO STUDY; NONHUMAN; PATHOGENESIS; PROTEUS MIRABILIS; RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRULENCE;

EID: 34247860661     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2007.19.2.152     Document Type: Article

References (29)

1. Livermore, DM. Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis 2003; 36 (suppl 1): S11-23.
2. Wood MJ, Moellering RC. Microbial resistance: bacteria and more. Clin Infect Dis 2003; 36 (suppl 1): S2-3.
3. Craig WA. Pharmacokinetics of antibiotics with special emphasis on cephalosporins. Clin Microbiol Infect 2000; 6 (Suppl. 3): 46-49.
4. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1-12.
5. Howard DH, Scott RD, Packard R, Jones DA. The global impact of drug resistance. Clin Infect Dis 2003; 36 (suppl 1): S4-10.
6. Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003; 36 (suppl 1): S42-50.
7. Braga PC, Dal Sasso M, Sala MT. Sub-MIC concentrations of cefodizime interfere with various factors affecting bacterial virulence. J Antimicrob Chemother 2000; 45: 15-25.
8. Debbia EA. Filamentation promotes F-lac loss in Escherichia coli K12. J Gen Microbiol 1992; 138: 2083-2091.
9. Debbia EA, Massaro S, Campora U, Schito GC. Inhibition of F'lac transfer by various antibacterial drugs in Escherichia coli. Microbiologica 1994; 17: 65-68.
10. Lorian V, Gemmel GC. Effects of low antibiotic concentrations on bacterial ultrastructure, virulence, and susceptibility to immunodefenses. In "Antibiotics in laboratory medicine" 4th Edn (Lorian, V Ed.), Williams and Wilkins, Baltimore, MD, 1996: 397-452.
11. Marchese A, Debbia EA, Massaro S, Campora U, Schito GC, Brodimoprim: effects of subminimal inhibitory concentrations on virulence traits of respiratory and urinary tract pathogens, and on plasmid transfer and stability. J Chemother 1996; 8: 171-177.
12. Molinari G, Guzmàn CA, Pesce A, Schito GC. Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J Antimicrob Chemother 1993; 31: 681-688.
13. Ochi H, Ohtsuka H, Yokota S-I, et al. Inhibitory activity on bacterial motility and in vivo protective activity of human monoclonal antibodies against flagella of Pseudomonas aeruginosa. Infect Immun 1991; 59: 550-554.
14. Saverino D, Debbia EA, Marchese A, PesceA, Botta GA, Schito GC. Plasmid loss from gram-negative bacteria exposed to sub-inhibitory concentrations of β-lactam drugs and azithromycin. Microbiologica 1993; 16: 343-350.
15. Shibl AM. Effect of antibiotics on adherence of microorganisms to epithelial cell surfaces. Rev Infect Dis 1985; 7: 51-65.
16. Shryock TR, Mortensen JE, Baumholtz M. The effects of macrolides on the expression of bacterial virulence mechanisms. J Antimicrob Chemother 1998; 41:505-512.
17. Sokol PA, Ohman DE, Iglewsky BH. A more sensitive plate assay for detection of protease production by Pseudomonas aeruginosa. J Clin Microbiol 1979; 9: 538-540.
18. Takeoka K, Ichimiya T, Yamasaki T, Nasu M. The in vitro effect of macrolides on the interaction of human polymorphonuclear leukocytes with Pseudomonas aeruginosa in biofilm. Chemotherapy 1998; 44: 190-197.
19. Schito GC, Georgopoulos A, Prieto J. Antibacterial activity of oral antibiotics against community-acquired respiratory pathogens from three European countries. J Antimicrob Chemother 2002; 50 Suppl:7-11.
20. Heisig P. High-level fluoroquinolone resistence in a Salmonella typhimurium isolate due to alteration in both gyrA and gyrB genes. J Antimicrob Chemother 1993; 32: 367-377.
21. Heisig P Wiedemann B. Use of a broad-host-range gyrA plasmid for genetic characterization of fluoroquinolone-resistant gram-negative bacteria. Antimicrob Agents Chemother 1991; 35: 2031-2036.
22. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard- Sixth Edition: M7-A6 and supplement M100-S14, Wayne, PA, 2003.
23. Freeman DJ, Falkiner FR, Keane CT. New method for detecting "slime" production by coagulase negative staphylococci. J Clin Pathol 1989; 42: 872-874.
24. Reifsteck F, Wee S, Wilkinson BJ. Hydrophobicity-hydrophilicity of staphylococci. J Med Microbiol 1987; 24: 65-73.
25. Doetsch RN. Determinative methods in light microscopy. In "Manual of methods for general bacteriology" American Society for Microbiology, Washington, 1981: 21-33.
26. Willetts N. Conjugation. In Methods in Microbiology 21, Edited by P.M. Bennet & J. Grinsted. Academic Press, London. 1988: 49-77.
27. Anderson GG, SM Scott, SJ Hultgren. Host subversion by formation of intracellular bacterial communities in the urinary tract. Microb Infect 2004; 6: 1094-1101.
28. Anderson GG, KW Dodson, TM Hooton, SJ Hultgren. Intracellular bacterial communities of uropathogenic Escherichia coli in urinary tract pathogenesis. Trends Microbiol 2004; 12: 424-430.
29. Helinski DR. Introduction to plasmids: a selective view of their history. In Funnel BE and Phillips G. Eds. Plasmid Biology 2004: 1-21.